Abstract
BackgroundVobarilizumab is a Nanobody® consisting of an anti-IL-6R domain and an anti-human serum albumin domain in development for treatment of RA. The efficacy and safety were assessed in a 24-week...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have